CEPI
@cepi.net
Coalition for Epidemic Preparedness Innovations (CEPI). Working to end epidemics & pandemics by developing new vaccines for a safer world. #100DaysMission
“Standardized clinical assays, diagnostic assays and, ultimately, a vaccine are needed to prepare for future Nipah virus outbreaks.”
A CEPI-led publication in @Nature Health explores what the world needs to respond effectively to #Nipah outbreaks. www.nature.com/articles/s44...
A CEPI-led publication in @Nature Health explores what the world needs to respond effectively to #Nipah outbreaks. www.nature.com/articles/s44...
Research and development priorities for Nipah virus outbreak preparedness - Nature Health
Standardized clinical assays, diagnostic assays and, ultimately, a vaccine are needed to prepare for future Nipah virus outbreaks.
www.nature.com
January 16, 2026 at 12:30 PM
“Standardized clinical assays, diagnostic assays and, ultimately, a vaccine are needed to prepare for future Nipah virus outbreaks.”
A CEPI-led publication in @Nature Health explores what the world needs to respond effectively to #Nipah outbreaks. www.nature.com/articles/s44...
A CEPI-led publication in @Nature Health explores what the world needs to respond effectively to #Nipah outbreaks. www.nature.com/articles/s44...
🎙️ How do you stop a pandemic before it starts?
CEPI’s Valentina Bernasconi and Charles River’s Marie-Eve Poupart break it down: vaccines, lab tools & preparpring for a Disease X.
Listen to the full podcast:
www.criver.com/eureka/plann...
CEPI’s Valentina Bernasconi and Charles River’s Marie-Eve Poupart break it down: vaccines, lab tools & preparpring for a Disease X.
Listen to the full podcast:
www.criver.com/eureka/plann...
www.criver.com
January 15, 2026 at 3:50 PM
🎙️ How do you stop a pandemic before it starts?
CEPI’s Valentina Bernasconi and Charles River’s Marie-Eve Poupart break it down: vaccines, lab tools & preparpring for a Disease X.
Listen to the full podcast:
www.criver.com/eureka/plann...
CEPI’s Valentina Bernasconi and Charles River’s Marie-Eve Poupart break it down: vaccines, lab tools & preparpring for a Disease X.
Listen to the full podcast:
www.criver.com/eureka/plann...
Our new short communication in Vaccine outlines CEPI’s Coronavirus Vaccine Library: a preparedness effort to build and share antigen designs, assays and data across priority coronaviruses.
Read in full: sciencedirect.com/science/arti...
Read in full: sciencedirect.com/science/arti...
Initiation of a coronavirus vaccine library
Coronaviruses (CoVs) continue to pose a global health threat as they spill over from animal hosts to humans. The Coalition for Epidemic Preparedness I…
sciencedirect.com
January 14, 2026 at 3:13 PM
Our new short communication in Vaccine outlines CEPI’s Coronavirus Vaccine Library: a preparedness effort to build and share antigen designs, assays and data across priority coronaviruses.
Read in full: sciencedirect.com/science/arti...
Read in full: sciencedirect.com/science/arti...
Amid a Rift Valley fever outbreak in West Africa, the Nuffield Department of Medicine @ox.ac.uk and Serum Institute of India have entered into a $3.5m agreement supported by CEPI to create the world’s largest reserve of Oxford’s investigational Rift Valley fever vaccine💉
CEPI, Oxford, Serum create largest-ever reserve of investigational Rift Valley fever vaccine
CEPI helped spearhead the agreement to advance work to protect against potentially deadly viral disease currently affecting West Africa.
cepi.net
January 13, 2026 at 11:37 AM
Amid a Rift Valley fever outbreak in West Africa, the Nuffield Department of Medicine @ox.ac.uk and Serum Institute of India have entered into a $3.5m agreement supported by CEPI to create the world’s largest reserve of Oxford’s investigational Rift Valley fever vaccine💉
Can scientists design an all-in-one vaccine to protect against multiple deadly viruses, including Ebola, Sudan and Marburg?
@ox.ac.uk and partners, including the University of Leipzig and Moderna, are leading a new project with $26.7m from CEPI and @horizoneu.bsky.social.
cepi.net/ambitious-re...
@ox.ac.uk and partners, including the University of Leipzig and Moderna, are leading a new project with $26.7m from CEPI and @horizoneu.bsky.social.
cepi.net/ambitious-re...
Ambitious research aims to develop multivalent vaccines to protect against multiple deadly filoviruses
Backed by up to $26.7 million in funding, researchers will design and test vaccine candidates against viruses including Ebola, Sudan, Bundibugyo and Marburg.
cepi.net
January 8, 2026 at 11:02 AM
Can scientists design an all-in-one vaccine to protect against multiple deadly viruses, including Ebola, Sudan and Marburg?
@ox.ac.uk and partners, including the University of Leipzig and Moderna, are leading a new project with $26.7m from CEPI and @horizoneu.bsky.social.
cepi.net/ambitious-re...
@ox.ac.uk and partners, including the University of Leipzig and Moderna, are leading a new project with $26.7m from CEPI and @horizoneu.bsky.social.
cepi.net/ambitious-re...
AI is revolutionising how science can protect the world and its people against the threat of infectious disease outbreaks. Learn how CEPI is harnessing the power of AI to transform vaccine development for future epidemics or pandemics.
https://cepi.net/artificial-intelligence
https://cepi.net/artificial-intelligence
Artificial intelligence
AI is revolutionising how science can protect the world and its people against the threat of infectious disease outbreaks. Learn how CEPI is harnessing the power of AI to transform vaccine development...
cepi.net
January 7, 2026 at 7:44 AM
AI is revolutionising how science can protect the world and its people against the threat of infectious disease outbreaks. Learn how CEPI is harnessing the power of AI to transform vaccine development for future epidemics or pandemics.
https://cepi.net/artificial-intelligence
https://cepi.net/artificial-intelligence
CEPI’s Biosecurity Strategy—supported by funding from Global Affairs Canada—aims to bolster global health security, underscoring its commitment to tackling emerging epidemic and pandemic threats, whether they arise naturally, accidentally or through deliberate misuse.
https://cepi.net/biosecurity
https://cepi.net/biosecurity
Biosecurity
CEPI’s inaugural Biosecurity Strategy—supported by funding from Global Affairs Canada—aims to bolster global health security, underscoring its commitment to tackling emerging epidemic and pandemic thr...
cepi.net
January 6, 2026 at 10:36 AM
CEPI’s Biosecurity Strategy—supported by funding from Global Affairs Canada—aims to bolster global health security, underscoring its commitment to tackling emerging epidemic and pandemic threats, whether they arise naturally, accidentally or through deliberate misuse.
https://cepi.net/biosecurity
https://cepi.net/biosecurity
ICYMI: Check out CEPI CEO Dr Richard Hatchett's 2025 end of year reflections.
https://bit.ly/49iV573
https://bit.ly/49iV573
Reflections on 2025 – Richard Hatchett
CEPI CEO Dr Richard Hatchett shares his personal reflections on a watershed year for global health and looks towards a future in which truly global health security is within sight.
cepi.net
January 5, 2026 at 7:44 AM
ICYMI: Check out CEPI CEO Dr Richard Hatchett's 2025 end of year reflections.
https://bit.ly/49iV573
https://bit.ly/49iV573
The viruses that put humanity at greatest risk to date come from 25 or so virus families. It is these families that are most likely to produce the next deadly viral threat.
https://bit.ly/3EUmaAN
https://bit.ly/3EUmaAN
Getting to know humanity’s greatest threats - The Viral Most Wanted
Learn about the viral family approach and how it informs The Viral Most Wanted
cepi.net
January 2, 2026 at 7:51 AM
The viruses that put humanity at greatest risk to date come from 25 or so virus families. It is these families that are most likely to produce the next deadly viral threat.
https://bit.ly/3EUmaAN
https://bit.ly/3EUmaAN
To date, CEPI has made investments in over 75 vaccine candidates or platform technologies.
This includes advancing research against:
🔵 COVID-19
🔵 MERS
🔵 Nipah
🔵 Lassa fever
🔵 Chikungunya
🔵 Rift Valley fever
🔵 Disease X
🔵 Ebola
Find out more 👇https://cepi.net/priority-pathogens
This includes advancing research against:
🔵 COVID-19
🔵 MERS
🔵 Nipah
🔵 Lassa fever
🔵 Chikungunya
🔵 Rift Valley fever
🔵 Disease X
🔵 Ebola
Find out more 👇https://cepi.net/priority-pathogens
December 30, 2025 at 10:20 AM
To date, CEPI has made investments in over 75 vaccine candidates or platform technologies.
This includes advancing research against:
🔵 COVID-19
🔵 MERS
🔵 Nipah
🔵 Lassa fever
🔵 Chikungunya
🔵 Rift Valley fever
🔵 Disease X
🔵 Ebola
Find out more 👇https://cepi.net/priority-pathogens
This includes advancing research against:
🔵 COVID-19
🔵 MERS
🔵 Nipah
🔵 Lassa fever
🔵 Chikungunya
🔵 Rift Valley fever
🔵 Disease X
🔵 Ebola
Find out more 👇https://cepi.net/priority-pathogens
What if it took 100 days to make a safe and effective vaccine against any virus?
We could stay one step ahead of infectious diseases and outbreaks could be stopped before they ever spiralled into pandemics #100DaysMission
https://cepi.net/cepi-20-and-100-days-mission
We could stay one step ahead of infectious diseases and outbreaks could be stopped before they ever spiralled into pandemics #100DaysMission
https://cepi.net/cepi-20-and-100-days-mission
CEPI 2.0 and the 100 Days Mission
CEPI’s 2022-2026 strategy, known as CEPI 2.0, is helping to Prepare, Transform, and Connect the world so that it can respond to the next Disease X threat with a new vaccine in just three months.
cepi.net
December 23, 2025 at 10:32 AM
What if it took 100 days to make a safe and effective vaccine against any virus?
We could stay one step ahead of infectious diseases and outbreaks could be stopped before they ever spiralled into pandemics #100DaysMission
https://cepi.net/cepi-20-and-100-days-mission
We could stay one step ahead of infectious diseases and outbreaks could be stopped before they ever spiralled into pandemics #100DaysMission
https://cepi.net/cepi-20-and-100-days-mission
The Biospecimen Sourcing Initiative is a new global resource that aims to facilitate the timely, coordinated and ethical sourcing of biospecimens in an outbreak.
Specimens provide scientists with insights into the virus and how the body fends off an infection ⤵️ @path.org
cepi.net/disease-outb...
Specimens provide scientists with insights into the virus and how the body fends off an infection ⤵️ @path.org
cepi.net/disease-outb...
Disease outbreak survivors are key to future preparedness
A new global biospecimen access network aims to collect and share biological samples consistently and equitably.
cepi.net
December 20, 2025 at 1:49 PM
The Biospecimen Sourcing Initiative is a new global resource that aims to facilitate the timely, coordinated and ethical sourcing of biospecimens in an outbreak.
Specimens provide scientists with insights into the virus and how the body fends off an infection ⤵️ @path.org
cepi.net/disease-outb...
Specimens provide scientists with insights into the virus and how the body fends off an infection ⤵️ @path.org
cepi.net/disease-outb...
Reposted by CEPI
🚨 Exciting news for global health security: CEPI is supporting a pivotal Phase 3 trial to advance Moderna’s mRNA H5 pandemic influenza vaccine candidate (mRNA-1018) towards licensure and enable rapid, equitable access in the event of a flu pandemic.
CEPI to Fund Pivotal Phase 3 Trial for Moderna’s mRNA Pandemic Influenza Candidate
Partnership strengthens global preparedness against a significant pandemic threat
cepi.net
December 18, 2025 at 1:44 PM
🚨 Exciting news for global health security: CEPI is supporting a pivotal Phase 3 trial to advance Moderna’s mRNA H5 pandemic influenza vaccine candidate (mRNA-1018) towards licensure and enable rapid, equitable access in the event of a flu pandemic.
🚨 Exciting news for global health security: CEPI is supporting a pivotal Phase 3 trial to advance Moderna’s mRNA H5 pandemic influenza vaccine candidate (mRNA-1018) towards licensure and enable rapid, equitable access in the event of a flu pandemic.
CEPI to Fund Pivotal Phase 3 Trial for Moderna’s mRNA Pandemic Influenza Candidate
Partnership strengthens global preparedness against a significant pandemic threat
cepi.net
December 18, 2025 at 1:44 PM
🚨 Exciting news for global health security: CEPI is supporting a pivotal Phase 3 trial to advance Moderna’s mRNA H5 pandemic influenza vaccine candidate (mRNA-1018) towards licensure and enable rapid, equitable access in the event of a flu pandemic.
In our Innovation for Impact story, we spoke with icddr,b’s Dr K Zaman and CEPI’s Nipah programme lead, Rick Jarman, to explore the impact of CEPI's $150 million Nipah R&D portfolio and how it's helping the world prepare to confront one of the most lethal viral threats.
Closing in on protection against deadly Nipah virus
Discover how CEPI and partners are preparing the world to face down a future Nipah virus outbreak.
cepi.net
December 17, 2025 at 12:46 PM
In our Innovation for Impact story, we spoke with icddr,b’s Dr K Zaman and CEPI’s Nipah programme lead, Rick Jarman, to explore the impact of CEPI's $150 million Nipah R&D portfolio and how it's helping the world prepare to confront one of the most lethal viral threats.
CEPI is backing a second $198,000 project with GENSPEED Biotech to speed up vaccine quality testing. The rapid, automated assay can detect residual proteins in ~20 minutes—far faster than today’s 3-hour methods.
December 12, 2025 at 10:53 AM
CEPI is backing a second $198,000 project with GENSPEED Biotech to speed up vaccine quality testing. The rapid, automated assay can detect residual proteins in ~20 minutes—far faster than today’s 3-hour methods.
Reposted by CEPI
📢 A world first: CEPI-funded Nipah virus vaccine candidate enters Phase II clinical trials.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
University of Oxford launches world’s first Phase II Nipah virus vaccine trial
CEPI-funded Phase II trial launches in Bangladesh
cepi.net
December 9, 2025 at 10:16 AM
📢 A world first: CEPI-funded Nipah virus vaccine candidate enters Phase II clinical trials.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
Reposted by CEPI
During a disease outbreak, #VaccineDevelopment efforts rely on biological samples from survivors. With @cepi.net, we conducted a simulation exercise to test the design and development of a new network that aims to collect and share these samples consistently and equitably: https://bit.ly/440DQ7O
December 8, 2025 at 4:19 PM
During a disease outbreak, #VaccineDevelopment efforts rely on biological samples from survivors. With @cepi.net, we conducted a simulation exercise to test the design and development of a new network that aims to collect and share these samples consistently and equitably: https://bit.ly/440DQ7O
Reposted by CEPI
The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus.
Find out more ⬇️ @ovg.ox.ac.uk | @cepi.net
Find out more ⬇️ @ovg.ox.ac.uk | @cepi.net
First volunteer receives Lassa Fever vaccine in cutting-edge Oxford
The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus.
www.ox.ac.uk
December 9, 2025 at 2:24 PM
The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus.
Find out more ⬇️ @ovg.ox.ac.uk | @cepi.net
Find out more ⬇️ @ovg.ox.ac.uk | @cepi.net
📢 A world first: CEPI-funded Nipah virus vaccine candidate enters Phase II clinical trials.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
University of Oxford launches world’s first Phase II Nipah virus vaccine trial
CEPI-funded Phase II trial launches in Bangladesh
cepi.net
December 9, 2025 at 10:16 AM
📢 A world first: CEPI-funded Nipah virus vaccine candidate enters Phase II clinical trials.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
The @ox.ac.uk has launched the world’s first Phase II trial of its ChAdOx1 NipahB vaccine in Bangladesh. This is the most advanced stage of clinical testing for a Nipah vaccine to date.
📣 The Republic of Korea's Ministry of Foreign Affairs has announced new $18.9 million support to CEPI to bolster efforts to protect against the next deadly pandemic and boost international health security 🇰🇷
cepi.net/korea-steps-...
cepi.net/korea-steps-...
Korea steps up pandemic response with $18.9m investment in CEPI
The new financial contribution agreement was signed today at a meeting with Ambassador Minjeong Seo, Ambassador of the Republic of Korea to Norway and CEPI CEO Dr Richard Hatchett.
cepi.net
December 5, 2025 at 3:08 PM
📣 The Republic of Korea's Ministry of Foreign Affairs has announced new $18.9 million support to CEPI to bolster efforts to protect against the next deadly pandemic and boost international health security 🇰🇷
cepi.net/korea-steps-...
cepi.net/korea-steps-...
📣The first volunteer has received a dose of @ox.ac.uk's Lassa fever vaccine candidate in a Phase I trial funded by CEPI.
The deadly haemmorhagic fever causes annual outbreaks across West Africa, however no vaccine is currently available for use (1/2).
The deadly haemmorhagic fever causes annual outbreaks across West Africa, however no vaccine is currently available for use (1/2).
First volunteer receives Lassa fever vaccine in cutting-edge Oxford trial
The CEPI-funded research study will assess the safety and immune response of Oxford's ChAdOx1 Lassa vaccine.
cepi.net
December 4, 2025 at 12:23 PM
📣The first volunteer has received a dose of @ox.ac.uk's Lassa fever vaccine candidate in a Phase I trial funded by CEPI.
The deadly haemmorhagic fever causes annual outbreaks across West Africa, however no vaccine is currently available for use (1/2).
The deadly haemmorhagic fever causes annual outbreaks across West Africa, however no vaccine is currently available for use (1/2).
Last month, CEPI had the pleasure of welcoming Marjolijn Sonnema, Vice Minister of Health of the Netherlands, to The
Aurum Institute in Johannesburg.
Aurum Institute in Johannesburg.
December 1, 2025 at 3:02 PM
Last month, CEPI had the pleasure of welcoming Marjolijn Sonnema, Vice Minister of Health of the Netherlands, to The
Aurum Institute in Johannesburg.
Aurum Institute in Johannesburg.
CEPI’s November newsletter is out! 🗞️
This edition spotlights recent regulatory “pressure test” simulations in Brasilia and Mombasa, early clinical progress on a Lassa fever vaccine, new partnerships to speed up vaccine manufacturing and release, and lots more.
www.linkedin.com/pulse/pressu...
This edition spotlights recent regulatory “pressure test” simulations in Brasilia and Mombasa, early clinical progress on a Lassa fever vaccine, new partnerships to speed up vaccine manufacturing and release, and lots more.
www.linkedin.com/pulse/pressu...
Pressure testing the world’s rapid regulatory response capabilities
When a novel virus emerges that has epidemic or pandemic potential, decisions have to be made fast: which vaccine candidates to move into trials, how trials should be designed, how to share data, and ...
www.linkedin.com
November 28, 2025 at 11:04 AM
CEPI’s November newsletter is out! 🗞️
This edition spotlights recent regulatory “pressure test” simulations in Brasilia and Mombasa, early clinical progress on a Lassa fever vaccine, new partnerships to speed up vaccine manufacturing and release, and lots more.
www.linkedin.com/pulse/pressu...
This edition spotlights recent regulatory “pressure test” simulations in Brasilia and Mombasa, early clinical progress on a Lassa fever vaccine, new partnerships to speed up vaccine manufacturing and release, and lots more.
www.linkedin.com/pulse/pressu...
CEPI’s new publication lays out the blueprint for equitable access at the heart of the organisation’s outbreak R&D.
Our Pathogen Archetype Frameworks details four pathogen archetypes, which ultimately guide CEPI’s access funding, advocacy, and catalysing efforts.
Learn more in the blog ⬇️
Our Pathogen Archetype Frameworks details four pathogen archetypes, which ultimately guide CEPI’s access funding, advocacy, and catalysing efforts.
Learn more in the blog ⬇️
A blueprint for access at the heart of outbreak R&D | CEPI
Discover how the type of pathogen guides CEPI's approach to access
cepi.net
November 26, 2025 at 2:29 PM
CEPI’s new publication lays out the blueprint for equitable access at the heart of the organisation’s outbreak R&D.
Our Pathogen Archetype Frameworks details four pathogen archetypes, which ultimately guide CEPI’s access funding, advocacy, and catalysing efforts.
Learn more in the blog ⬇️
Our Pathogen Archetype Frameworks details four pathogen archetypes, which ultimately guide CEPI’s access funding, advocacy, and catalysing efforts.
Learn more in the blog ⬇️